HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroiku Kawakami Selected Research

Therapeutics

1/2019Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
1/2018Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
2/2015Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
10/2013Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.
6/2009Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients.
1/2007Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroiku Kawakami Research Topics

Disease

4Chronic Hepatitis B
01/2019 - 05/2007
3Chronic Hepatitis C
02/2015 - 01/2006
1Hepatitis
10/2013
1Hepatitis C
06/2009
1Infections
05/2007
1Hemolytic Anemia
01/2007

Drug/Important Bio-Agent (IBA)

3InterferonsIBA
01/2019 - 02/2015
3NucleotidesIBA
01/2019 - 10/2013
3NucleosidesIBA
01/2019 - 05/2007
3Ribavirin (Virazole)FDA LinkGeneric
02/2015 - 01/2007
3RNA (Ribonucleic Acid)IBA
10/2013 - 01/2006
2Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2019 - 01/2018
2AntigensIBA
01/2019 - 01/2018
2Hepatitis B e AntigensIBA
01/2018 - 10/2013
1DNA (Deoxyribonucleic Acid)IBA
01/2018
1nasIBA
10/2013
1Lamivudine (Epivir)FDA Link
05/2007
1lipoarabinomannan (LAM)IBA
05/2007
1Eicosapentaenoic AcidIBA
01/2007
1Interferon-alpha (Interferon Alfa)IBA
01/2007

Therapy/Procedure

6Therapeutics
01/2019 - 01/2007